

Ecraid Publications 2022-2026 (newest first)

Bonten M, Essink B, Hanning N, Leroux-Roels I, Masuet-Aumatell C, Natalini Martinez S, Amare Hailemariam H, Jandari G, Kwo Ton Ge Jua P, Servais C, et al. Immunogenicity and safety of co-administration of AS01_E-adjuvanted respiratory syncytial virus prefusion F protein vaccine and a COVID-19 mRNA vaccine in adults aged ≥50 years: a phase 3, randomized, non-inferiority trial, *Clinical Infectious Diseases*, 2026, ciag344.

<https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciag344/8702407>

Fromage Y, Hernandez Padilla AC, Vaidie J, Sayadi H, Barac A, Cremer OL, Garot D, Rouzé A, Daix T, Vintcent LEM, Jackson H, De Kraker MEA, van Werkhoven CH, Woillard JB, François B et al. A clinically actionable risk score for ventilator-associated pneumonia using interpretable machine learning, *CHEST Critical Care*. 2026, 100283, ISSN 2949-7884.

<https://www.sciencedirect.com/science/article/pii/S294978842600050X>

Hashmi M, Haniffa R, Jayakumar D, Beane A, Lorenzi E, Berry LR, Khoso MN, Khan QA, Kumar A, Kidwai AA, et al. Ivermectin for Critically and Noncritically Ill Hospitalized Patients With COVID-19: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP). *Crit Care Med*. 2026 May 8. Online ahead of print.

https://journals.lww.com/ccmjournal/fulltext/9900/ivermectin_for_critically_and_noncritically_ill.818.aspx

Karssen D, Hessels LM, Barten-Neiner G, Bauer W, Franch-Arroyo S, Fühner T, Hassiepen CO, Heigener DF, Hullegie S, Jahja R, Johnson KD et al. Serotype distribution and coverage by pneumococcal vaccines in hospitalised adults with pneumococcal pneumonia in Germany. *ERJ Open Research* 2026 12(3): 00946-2025.

<https://publications.ersnet.org/content/erjor/12/3/00946-2025>

Maxwell L, Shreedhar P, Gilyan R, Naccache M, Terry R. How do we measure data sharing in the biomedical sciences? A measurement systematic review of biomedical data sharing-related knowledge, attitudes and practices across stakeholder groups, data types and geographies. *BMJ Open* 2026;16:e100314

<https://bmjopen.bmj.com/content/16/3/e100314>

Jackson H, Hernandez AC, Vintcent L, Barac A, Cremer, O Daix T, De Waele J, Forcelledo L, Barraud O, Bonten M, Harbarth S, Francois B, van Werkhoven CH, de Kraker MEA. Perpetual observational study of the clinical and microbiological epidemiology of ventilator-associated pneumonia in Europe. *Crit Care* 30, 112 (2026)

<https://link.springer.com/article/10.1186/s13054-025-05753-5>

Prat-Aymerich C, Hessels L, Karssen D, Johnson KD, Hullegie S, Jahja R, Rodriguez-Baño R, François B, Blasi F, Chalmers JD et al. Rationale and design of the Pneumococcal Pneumonia Epidemiology, Urine Serotyping and Mental Outcomes (PNEUMO) study Europe. *ERJ Open Res.* 2025 Dec 1;11(6):00237-2025.

<https://publications.ersnet.org/content/erjor/11/6/00237-2025>

Niessen FA, Steens A, Knol MJ, Groenwold RHH, Bonten MJM, van Sorge NM, de Melker HE, van Werkhoven CH. Impact and vaccine effectiveness of PPV23 vaccination in adults aged 65 years or older in the Netherlands. *Clin Microbiol Infect.* 2025 Nov 12:S1198-743X(25)00553-1. Epub ahead of print.

<https://www.sciencedirect.com/science/article/abs/pii/S1198743X25005531>

Jackson H, Sauser J, van Werkhoven CH, Harbarth S, de Kraker MEA. Benefits of group sequential design and sample size re-estimation for randomised controlled trials evaluating the prevention of ventilator-associated pneumonia: a simulation study informed by real world data. *BMC Medical Research Methodology* 2025 Nov.

<https://link.springer.com/article/10.1186/s12874-025-02681-4>

Maxwell L, Arraes De Alencar Ximenes R, Debray TPA, Jaenisch T, Levis B, De Jong VMT, Shreedhar P, Carabali M, Gustafson P, Merson L. How to conduct an individual participant data meta-analysis in response to an emerging pathogen: Lessons learned from Zika and COVID-19. *Research Synthesis Methods*. 2025 Nov.

<https://www.cambridge.org/core/journals/research-synthesis-methods/article/how-to-conduct-an-individual-participant-data-metaanalysis-in-response-to-an-emerging-pathogen-lessons-learned-from-zika-and-covid19/4DECF9E18524A624718A7FFEFE7465EF>

Garlasco J, Arieti F, Morra M, Tebon M, Ortiz D, Pezzani MD, Odoj K, Manco F, Cassini A, Harbarth S et al. The Emerging Resistance Index: tracking early resistance to new antibiotics. *The Lancet Infectious Diseases*. 10.1016/S1473-3099(25)00501-8.

<https://www.sciencedirect.com/science/article/abs/pii/S1473309925005018>

Bonten M, Schweitzer V, van Werkhoven H. Empiric antibiotics for moderate-severe community-acquired pneumonia: we ought to serve patients better! *Clin Microbiol Infect*. 2025 Nov;31(11):1779-1781. Epub 2025 Sep 3

[https://www.clinicalmicrobiologyandinfection.org/article/S1198-743X\(25\)00427-6/abstract](https://www.clinicalmicrobiologyandinfection.org/article/S1198-743X(25)00427-6/abstract)

van Hout D, Mouncey P, Harrison D, Bonten M, Derde L; REMAP-CAP European Regional Investigators; Angus DC, Anjum A, Annane D, Best-Lane J, Brunkhorst F et al. Hurdles for the Delivery of Multinational Randomized Clinical Trials. *JAMA Netw Open*. 2025 Jul 1;8(7):e2518503.

<https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2835887>

Rajakani SG, Xavier BB, Nguyen NM, Lin Q, Braspenning A, Plantinga NL, Wittekamp BHJ, Zarkotou O, Van Houdt R, Glupczynski Y et al. Characterization of genome-wide transpositions induced by colistin exposure in multi-drug-resistant *Klebsiella pneumoniae*. *Antimicrob Agents Chemother*. 2025 Jul 2;69(7):e0157424. doi: 10.1128/aac.01574-24. Epub 2025 May 19.

<https://journals.asm.org/doi/10.1128/aac.01574-24>

Haitsma Mulier JLG, Falcone M, Tiseo G, Azzini AM, Scardellato R, Franceschini E, Tafuri S, Merli M, Carević B, Roilides E et al. Postoperative risk of infection with klebsiella in adults - a retrospective case-control study. *J Hosp Infect.* 2025 Aug;162:26-35. doi: 10.1016/j.jhin.2025.04.036. Epub 2025 May 27.

[https://www.journalofhospitalinfection.com/article/S0195-6701\(25\)00156-2/fulltext](https://www.journalofhospitalinfection.com/article/S0195-6701(25)00156-2/fulltext)

Guedes M, de la Serna Bazan A, Rubio-Martín E, Barrera Pulido L, Palomo L, Piljić A, Leclerc QJ, Aris E, Vella V, Dambrauskienė A et al. How to: share and reuse data—challenges and solutions from predicting the impact of monoclonal antibodies & vaccines on antimicrobial resistance project. *Clinical Microbiology and Infection*, 2025; 31, 753-760.

[https://www.clinicalmicrobiologyandinfection.org/article/S1198-743X\(25\)00031-X/fulltext](https://www.clinicalmicrobiologyandinfection.org/article/S1198-743X(25)00031-X/fulltext)

REMAP-CAP Investigators; Derek C Angus. Effect of hydrocortisone on mortality in patients with severe community-acquired pneumonia: The REMAP-CAP Corticosteroid Domain Randomized Clinical Trial. *Intensive Care Med.* 2025 Apr;51(4):665-680. doi: 10.1007/s00134-025-07861-w. Epub 2025 Apr 22. Erratum in: *Intensive Care Med.* 2025 Jul;51(7):1415.

<https://link.springer.com/article/10.1007/s00134-025-07861-w>

Jackson H, Shou Y, Binte Mohamed Azad NA, Wen Chua J, Perez RL, Wang X, de Kraker MEA, Mo Y. A comparison of frequentist and Bayesian approaches to the Personalised Randomised Controlled Trial (PRACTical)—design and analysis considerations. *BMC Medical Research Methodology.* 2025 Mar.

<https://link.springer.com/article/10.1186/s12874-025-02537-x>

Noble CCA, McDonald E, Nicholson S, Biering-Sørensen S, Pittet LF, Byrne AL, Croda J, Dalcolmo M, Lacerda MVG, Lucas M et al. Characterising the SARS-CoV-2 nucleocapsid (N) protein antibody response. *J Infect.* 2025 Mar;90(3):106436. doi: 10.1016/j.jinf.2025.106436. Epub 2025 Feb 6

[https://www.journalofinfection.com/article/S0163-4453\(25\)00030-1/fulltext](https://www.journalofinfection.com/article/S0163-4453(25)00030-1/fulltext)

Odoj K, Garlasco J, Pezzani MD, Magnabosco C, Ortiz D, Manco F, Galia L, Foster SK, Arieti F, Tacconelli E. Tracking Candidemia Trends and Antifungal Resistance Patterns across Europe: An In-Depth Analysis of Surveillance Systems and Surveillance Studies. *J. Fungi* 2024, 10(10), 685;

<https://www.mdpi.com/2309-608X/10/10/685>

Durazzi F, Pezzani MD, Arieti F, Simonetti O, Canziani LM, Carrara E, Barbato L, Onorati F, Remondini D, Tacconelli E. Modelling antimicrobial resistance transmission to guide personalized antimicrobial stewardship interventions and infection control policies in healthcare setting: a pilot study. *Sci Rep* 13, 15803 (2023).

<https://www.nature.com/articles/s41598-023-42511-5>

Zaeck LM, Lamers MM, van Royen ME, Götz H, Shamier MC, van Leeuwen LPM, Schmitz KS, Alblas K, van Efferen S, Bogers S et al. Low levels of monkeypox virus-neutralizing antibodies after MVA-BN vaccination in healthy individuals. *Nat Med* 29, 270–278 (2023).

<https://www.nature.com/articles/s41591-022-02090-w>

Hassoun-Kheir N, van Werkhoven CH, Dunning J, Jaenisch T, van Beek J, Bielicki J, Butler C, Francois B, Harbarth S, Hernandez Padilla AC et al. Perpetual Observational Studies: New strategies to support efficient implementation of observational studies and randomized trials in the infectious diseases arena. *Clin Microbiol Infect.* 2022 Dec;28(12):1528-1532. doi: 10.1016/j.cmi.2022.07.024. Epub 2022 Aug 5.

<https://arxiv.org/abs/2208.03992>

van Beek J, Fraaij PLA, Giaquinto C, Shingadia D, Horby P, Indolfi G, Koopmans M. Acute hepatitis study group. Case numbers of acute hepatitis of unknown aetiology among children in 24 countries up to 18 April 2022 compared to the previous 5 years. *Euro Surveill.* 2022;27(19):pii=2200370.

<https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2022.27.19.2200370>
